Skip to main content

Gordon Carl L's Form 4 filing

Theseus Pharmaceuticals, Inc. (THRX) · filed Oct 14, 2021

Accession no.
0000899243-21-040256
Filed
Oct 14, 2021
Trade date
Oct 12, 2021
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market purchases total $10.0M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Gordon Carl LCIK 0001282930Director, 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 12, 2021Common StockCConversionAcquired+15,777,018–F2–15,777,018Indirect
Oct 12, 2021Common StockCConversionAcquired+436,650–F2–436,650Indirect
Oct 12, 2021Common StockPPurchaseAcquired+562,500$16.00+$9,000,00016,339,518Indirect
Oct 12, 2021Common StockPPurchaseAcquired+62,500$16.00+$1,000,000499,150Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Oct 12, 2021Common StockCConversionDisposed−14,903,718–F2–0Indirect
Oct 12, 2021Common StockCConversionDisposed−873,300–F2–0Indirect
Oct 12, 2021Common StockCConversionDisposed−436,650–F2–0Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The reported security converted into the issuer's Common Stock on a one-for-one basis automatically immediately prior to the closing of the issuer's initial public offering without payment of further consideration. The shares have no expiration date.

Referenced by the price of 2 transactions in Table I and 3 transactions in Table II.

Read the full filing on SEC EDGAR (opens in a new tab)